On December 18, 2020 SOM Biotech reported its participation at the BIO-Partnering at JP Morgan Healthcare Conference 2021, being held virtually on January 11th – 15th (Press release, SOM Biotech, DEC 18, 2020, View Source;utm_medium=rss&utm_campaign=som-biotech-at-the-bio-partnering-jpm-virtual-event-2021 [SID1234573075]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference, a leading virtual partnering and business development initiative for the biotechnology industry organized by Biotechnology Innovation Organization, provides a One-on-One partnering platform to give companies access to potential strategic partners and qualified investors worldwide.

Raúl Insa, CEO of SOM Biotech highlights: "This is an excellent opportunity to present the advances in our portfolio and explore mutual interest with pharmaceutical and other life science companies to seek new drug discovery and development project based on our proprietary AI-based drug discovery technology – SOMAIPRO – which is one of the most powerful tools for drug discovery at present. After closing the remarkable year 2020, with positive results obtained from the Phase 2a related to our Huntington´s disease candidate SOM3355, we are also excited to present our pipeline assets and our strategic plan to investors interested in taking part in our future valuable launches and growth prospects".